Open AccessConcise Review: Bone Marrow Mononuclear Cells for the Treatment of Ischemic Syndromes: Medicinal Product or Cell Transplantation?
Author(s) -
Cuende Natividad,
Rico Laura,
Herrera Concha
Publication year - 2012
Publication title -
stem cells translational medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.781
H-Index - 71
eISSN - 2157-6580
pISSN - 2157-6564
DOI - 10.5966/sctm.2011-0064
Subject(s) - bone marrow , transplantation , medicine , neovascularization , regeneration (biology) , regenerative medicine , cell therapy , stem cell , cancer research , immunology , bioinformatics , angiogenesis , biology , surgery , microbiology and biotechnology
The Committee for Advanced Therapies of the European Medicines Agency recently classified autologous bone marrow‐derived mononuclear cells and CD133+ stem cells as tissue‐engineered products when intended for regeneration through stem cell‐induced angiogenesis in ischemic heart tissue. These scientific recommendations are reviewed in light of the scientific knowledge acquired over the last few years about the mechanisms of postnatal neovascularization. The negative impact that the consideration of these treatments as medicinal products, instead of cell transplants, will have on European public health services is also analyzed.